Type 2 Biomarkers as Mediators of Clinical Remission With Biologics in Severe Asthma
Duong Duc Pham, Hyouk‐Soo Kwon, Woo‐Jung Song, You Sook Cho, Sei Won Lee, Ga‐Young Ban, Taehoon Lee, So‐Young Park, Young‐Hee Nam, Byung‐Jae Lee, Jin An, Chan Sun Park, Hyo‐In Rhyou, Joo‐Hee Kim, Hye‐Kyung Park, Sang‐Ha Kim, Min‐Suk Yang, Min‐Hye Kim, Kyung‐Min Ahn, Ji‐Su Shim, Jeong‐Hee Choi, Sujeong Kim, Jae‐Woo Jung, Han‐Ki Park, Byung‐Keun Kim, Ji‐Hyang Lee, Young Chan Kim, Sang Min Lee, Sung‐Yoon Kang, Jae‐Woo Kwon, Gyu Young Hur, Ji‐Yong Moon, Kyoung‐Hee Sohn, Mi‐Ae Kim, Sae‐Hoon Kim, Sun‐Young Yoon, An‐Soo Jang, Sang‐Hoon Kim, So Young Park, Hyun Jung Jin, So Ri Kim, Jae‐Hyun Lee, Pankaj Bhavsar, Ian M. Adcock, Piers Dixey, Nazanin Zounemat Kermani, Freda Yang, Pujan H. Patel, Kian Fan Chung, Tae‐Bum Kim
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Table S1: Baseline characteristics of the Con-Tx, anti-IL5/IL5R therapy, and anti-IL4R groups in the mediation analysis datasets. Table S2: Sensitivity analysis of mediation effects across varying ρ (rho) values. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.